French pharmaceutical company Sanofi has reported results from its Phase III IRAKLIA trial, which evaluated Sarclisa (isatuximab) as a potential treatment for multiple myeloma (MM). The trial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback